Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cellular and biochemical mechanisms of obesity / / Paramjit S. Tappia, Bram Ramjiawan and Naranjan S. Dhalla, editors
| Cellular and biochemical mechanisms of obesity / / Paramjit S. Tappia, Bram Ramjiawan and Naranjan S. Dhalla, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (420 pages) |
| Disciplina | 574.192 |
| Collana | Advances in biochemistry in health and disease |
| Soggetto topico |
Biochemistry
Obesitat Trastorns del metabolisme |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-84763-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910513582303321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Dietary phytochemicals : a source of novel bioactive compounds for the treatment of obesity, cancer and diabetes / / Chukwuebuka Egbuna, Sadia Hassan, editors
| Dietary phytochemicals : a source of novel bioactive compounds for the treatment of obesity, cancer and diabetes / / Chukwuebuka Egbuna, Sadia Hassan, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (262 pages) |
| Disciplina | 615.321 |
| Soggetto topico |
Phytochemicals - Health aspects
Fitoquímica Nutrició Biotransformació (Metabolisme) Càncer Obesitat Diabetis |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-72999-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- Etiology of Obesity, Cancer, and Diabetes -- 1 Introduction -- 2 Obesity -- 2.1 Etiology of Obesity -- 2.2 Biological Factors -- 2.2.1 Genetics -- Monogenic Obesity -- Syndromic Obesity -- Polygenic Obesity -- 2.2.2 Brain-gut Axis -- 2.2.3 Prenatal Determinants -- 2.2.4 Pregnancy -- 2.2.5 Menopause -- 2.2.6 Physical Disability -- 2.2.7 Gut Microbiome -- 2.3 Environmental Factors -- 2.3.1 Obesogenic Environment -- 2.3.2 Socio-Economic Factors -- 2.3.3 Environmental Chemicals and Obesity -- 2.4 Behavioral Factors -- 2.4.1 Increased Calorie Intake and Eating Habits -- 2.4.2 Sedentary Lifestyle and Less Physical Activity -- 2.4.3 Insufficient Sleep -- 2.4.4 Quitting Smoking -- 3 Cancer -- 3.1 Major Types of Cancer -- 3.2 Causes of Cancer -- 3.2.1 Diet and Physical Activity -- 3.2.2 Use of Addictive Substances -- 3.2.3 Sex and Reproductive Health -- 3.2.4 Environmental Factors -- 3.2.5 Genetics -- 4 Diabetes Mellitus -- 4.1 Causes of Type 1 Diabetes Mellitus -- 4.1.1 Genetic Susceptibility Factors -- 4.1.2 Virus-Related Contagions -- 4.1.3 Role of Environment -- 4.2 Etiology of Type 2 Diabetes Mellitus -- 5 Conclusion -- References -- Pathophysiology of Obesity and Diabetes -- 1 Introduction -- 2 Obesity and Body Mass Index -- 3 Pathophysiology of Obesity -- 3.1 Development of Fat Cells -- 3.2 Fat Cell Metabolism -- 3.3 Oxidative Stress -- 3.4 Weight Stigma -- 4 Role of Different Factors in the Pathophysiology of Obesity -- 4.1 Pathophysiology of Obesity and the Role of Autonomic Nervous System -- 4.2 Osteopontin and Obesity -- 4.3 Obesity and Renal Disease -- 5 Maternal Obesity -- 6 Potential Role of Gut Inflammation in Disease Development -- 7 Childhood Obesity -- 8 Pathophysiology of Diabetes -- 8.1 Etiology of Diabetes -- 8.2 Role of Genetics in Development of T2DM.
8.3 Role of Environmental Determinants in the Development of T2DM -- 8.4 Insulin Resistance -- 8.5 The Role of Glucagon -- 8.6 Somatostatin -- 9 Conclusion -- References -- Pathophysiology of Obesity and Cancer: Drugs and Signaling Targets -- 1 Introduction -- 2 Pathophysiology of Obesity and Cancer -- 3 History of Anti-obesity Drugs -- 4 How to Treat Obesity? -- 5 Different Targets in Brain to Treat Obesity -- 5.1 Serotoninergic System -- 5.2 Noradrenergic System -- 5.3 Dopaminergic System -- 6 Link Between Obesity and Cancer -- 7 Drugs Targeting Cancer Cells -- 8 Drugs Targeting the Tumor Microenvironment's Cellular and Molecular Components -- 9 Changes in the Pharmacokinetics -- 10 Changes in Microbiota -- 11 Combination Therapy -- 12 Conclusion -- References -- Peptides Involved in Body Weight Regulation -- 1 Introduction -- 2 Appetite, Food Intake, and Obesity -- 3 Peptides and Body Weight -- 3.1 Effects of Hormonal Peptides -- 3.1.1 Orexigenic Peptides -- 3.1.2 Anorexigenic Peptides -- 3.1.3 Effects of Hypothalamic Peptides -- 3.2 Bioactive Peptides and Body Weight -- 4 Conclusion -- References -- Insulin Resistance: A Link Between Obesity and Cancer -- 1 Introduction -- 2 Obesity and Cancer -- 3 Diabetes and Cancer -- 4 Obesity and Diabetes -- 5 Mechanism Linking Insulin Resistance to Obesity and Cancer -- 6 Drugs to Treat Insulin Resistance -- 6.1 Metformin -- 6.2 Thiazolidinediones -- 6.3 Insulin Analogues -- 7 Challenges in Prevention and Treatment -- 8 Conclusion -- References -- Role of Cytoskeletal Protein, Actin in Various Diseases -- 1 Introduction -- 2 Microfilaments or Actin Filaments -- 2.1 Role in Cancer Metastasis and Tumor Angiogenesis -- 2.2 Role in Cytokinesis -- 2.3 Role in Cellular Signaling and Transport -- 2.4 Role in Immunodeficiency -- 2.5 Role in Fertilization of Eggs -- 2.6 Role in Neuronal Plasticity. 2.7 Role in Neurodegenerative Diseases -- 2.8 Role in Epigenetic Control -- 2.9 Role in Muscle Contraction -- 3 Conclusions -- References -- Diabetes Mellitus and it Management with Plant-Based Therapy -- 1 Introduction -- 2 Classification of Diabetes -- 2.1 Type I Diabetes Mellitus (T1DM) -- 2.2 Type II Diabetes Mellitus (T2DM) -- 2.3 Gestational DM (GDM) -- 3 Risk Factors of Diabetes -- 4 Pathophysiology -- 5 Screening and Diagnosis -- 6 Management -- 6.1 Through Lifestyle and Diet Modification -- 6.2 Pharmacological Agents -- 6.3 Plant Based Therapy -- 6.3.1 Mechanisms Underlying Herbal Anti-Diabetic Therapies -- 6.3.2 Classification of Plant-Based Anti-Diabetics -- 7 Conclusion -- References -- Fruits and Vegetables as Sources of Functional Phytochemicals for the Prevention and Management of Obesity, Diabetes, and Cancer -- 1 Introduction -- 2 Classification of Phytochemicals -- 2.1 Polyphenols -- 2.2 Terpenoids -- 2.3 Thiols -- 3 Health Benefits and Nutritional Value of Certain Fruits and Vegetables -- 3.1 Tomatoes -- 3.2 Grapes and Berries -- 3.3 Nuts -- 3.4 Citrus -- 3.5 Brassica Vegetables -- 3.6 Mushrooms -- 3.7 Kiwi -- 3.8 Cladodes -- 3.9 Carrots -- 3.10 Potatoes -- 3.11 Onion and Garlic -- 4 The Effect of Consuming Fruits and Vegetables on Some Diseases -- 4.1 Cancer -- 4.2 Obesity -- 4.3 Diabetes -- 5 Conclusion -- References -- Spices for Diabetes, Cancer and Obesity Treatment -- 1 Introduction -- 2 Anti-diabetic Effect of Spices -- 2.1 Fenugreek -- 2.2 Cinnamon -- 2.3 Garlic and Onion -- 2.4 Turmeric -- 2.5 Cumin Seeds -- 2.6 Ginger -- 3 Spices in the Treatment of Cancer -- 3.1 Basil -- 3.2 Caraway -- 3.3 Cardamom -- 3.4 Rosemary -- 3.5 Cumin -- 3.6 Turmeric -- 3.7 Garlic -- 3.8 Black Pepper -- 3.9 Red Chili -- 3.10 Ginger -- 3.11 Saffron -- 4 Spices in the Treatment of Obesity -- 4.1 Ginger -- 4.2 Turmeric -- 4.3 Garlic. 4.4 Red Pepper -- 5 Conclusion -- References -- MicroRNAs as Targets of Dietary Phytochemicals in Obesity and Cancer -- 1 Introduction -- 2 Phytochemical Modulated miRNAs and Its Role in Obesity -- 3 MicroRNAs as Phytochemicals Targets in Carcinogenesis -- 4 Dietary Phytochemicals and miRNA -- 4.1 Resveratrol -- 4.2 Genistein -- 4.3 Conjugated Linoleic Acids -- 4.4 Cinnamic Acid and Cinnamaldehyde -- 4.5 Ajoene -- 4.6 Curcumin -- 4.7 Epigallocatechin-3-Gallate -- 4.8 Quercetin -- 5 Conclusion -- References -- Natural Phenolic Compounds as Anti-obesity and Anti-cardiovascular Disease Agent -- 1 Introduction -- 2 Effects of Natural Phenolic Compounds on Oil and Fat Metabolism -- 3 Binding Bile Salt to Inhibit Emulsification of Lipids -- 3.1 In Vitro Studies -- 4 Pancreatic Lipase Inhibition -- 4.1 In Vitro Studies -- 4.2 In Silico Modeling Studies -- 4.3 Increase Fecal Lipid Excretion -- 4.4 Animal Models -- 4.5 Clinical Research -- 5 Gut Microbiota as Potential Targets -- 6 Reduction of Lipogenesis and Inflammation in Adipose Tissue and Liver -- 6.1 In Vitro Studies by Cell Models -- 6.2 Animal Models -- 7 Suppression of Lipogenic Enzyme Fatty Acid Synthase (FAS) in Cell -- 7.1 Cell Model -- 7.2 Animal Models -- 8 Increase of Lipolysis in Cell -- 9 Inhibition of Adipocyte Differentiation and Growth -- 10 Anti-atherosclerosis by Natural Phenolic Compounds -- 11 Conclusion -- References -- Harnessing the Potential of Phytochemicals for Breast Cancer Treatment -- 1 Introduction -- 2 Statistical Evidence Including the Indian Scenario -- 3 Current Treatments Strategies for Breast Cancer -- 3.1 Chemotherapy -- 3.2 Surgery -- 3.3 Gene Therapy -- 3.4 Oncogenes Inactivation -- 3.5 Augmentation of Tumor Suppresser Genes -- 3.5.1 BRCA1 and BRCA2 -- 3.5.2 Androgen Receptor -- 3.5.3 Immunomodulation -- 3.5.4 Endocrine (Antihormonal) Treatment. 3.5.5 Inclination Towards Phytochemicals -- 4 Phytochemicals for Breast Cancer Therapy -- 4.1 Plumbagin -- 4.2 Apigenin -- 4.3 Isothiocyanate -- 4.4 Quercetin -- 4.5 Curcumin -- 4.6 Catechins -- 4.7 Lycopene -- 4.8 Hesperidin -- 4.9 Anthocyanin -- 4.10 Colchicine Alkaloid -- 4.11 Polyphyllin D -- 4.12 Genistein -- 4.13 Resveratrol -- 4.14 Berberine -- 5 Pharmaceutical Compounding of Phytochemicals -- 6 Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910495214003321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The economics of obesity : poverty, income inequality, and health / / Tahereh Alavi Hojjat
| The economics of obesity : poverty, income inequality, and health / / Tahereh Alavi Hojjat |
| Autore | Hojjat Tahereh Alavi <1953-> |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (178 pages) |
| Disciplina | 362.196398 |
| Soggetto topico |
Obesity - Economic aspects
Obesitat Condicions econòmiques Desigualtat social Pobresa |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-78487-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- References -- Preface -- References -- Acknowledgments -- Contents -- About the Author -- Abbreviations -- List of Figures -- List of Tables -- Chapter 1: Introduction: The Magnitude of the Obesity Problem -- The Magnitude of the Obesity Problem -- References -- Chapter 2: Different Perspectives on Causes of Obesity -- References -- Chapter 3: Consequences of Obesity -- References -- Chapter 4: Economic Analysis: Behavioral Patterns, Diet Choice, and the Role of Government -- Rational Obesity Model -- An Alternative Model -- References -- Chapter 5: Socioeconomic Factors: Poverty and Obesity -- Income Inequality and Health -- References -- Chapter 6: Income and Wealth Inequality and Obesity -- Measure and Sources of Inequality -- References -- Chapter 7: Data and Methodology: Empirical Investigation of the Relationship Among Obesity, Income Inequality, and Poverty -- Model and Methodology -- Specification of the Model -- Methodology -- Results Discussion -- Causality Test -- Appendix -- References -- Chapter 8: Obesity and Socioeconomic Status: Case Study of Peruvian Women -- Poverty, Inequality, and Obesity in Peru -- Model to Test Income Inequality, Poverty, and Obesity in Peru -- Model and Methodology -- Result Discussion -- Causality Test -- Concluding Comments -- Appendix: Supplemental Tables and Figures -- References -- Chapter 9: Social Mobility and Health -- Defining Social Mobility -- Income Inequality and Social Mobility -- Intergenerational Mobility -- Income Inequality and Social Mobility Among Different Racial and Ethnic Groups -- Poverty, Education, and Economic Mobility -- Wealth and Economic Mobility -- Effect of Income on Health and Social Mobility -- References -- Chapter 10: Food Policies, Government Interventions, and Reducing Poverty -- Menu Labeling.
Taxation, Subsidization, and Role of Income Inequality -- Reducing Poverty, Learning Gap, and Access to Healthy Food in Low-Income Areas -- Food Advertising Regulation and the Roles of Technology -- References -- Chapter 11: Concluding Comments -- References -- Glossary of Terms -- Index. |
| Record Nr. | UNINA-9910495351703321 |
Hojjat Tahereh Alavi <1953->
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Food addiction, obesity, and disorders of overeating : an evidence-based assessment and clinical guide / / Claire E. Wilcox
| Food addiction, obesity, and disorders of overeating : an evidence-based assessment and clinical guide / / Claire E. Wilcox |
| Autore | Wilcox Claire E. |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (224 pages) |
| Disciplina | 616.8526 |
| Soggetto topico |
Compulsive eating
Trastorns de la conducta alimentària Trastorns de la gana Obesitat |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-83078-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Introduction: Obesity, Eating Disorders and Food Addiction: Towards a Synthesis -- References -- Contents -- Contributors -- Part I: Standard Approaches to Clinical Assessment and Treatment of Obesity and Binge Eating Disorder (BED) -- 1: Determinants of Body Weight: Metabolism and the Homeostatic System -- 1.1 Energy Balance -- 1.2 Metabolism -- 1.3 Why Weight Gain Is So Easy and Weight Loss So Hard -- 1.4 Homeostatic Feeding Mechanisms -- 1.4.1 The Hypothalamus -- 1.4.2 Key Neuropeptides -- 1.4.3 Other Factors -- 1.5 Neuropeptides, Obesity, and Disordered Eating -- 1.6 Conclusion -- References -- 2: Obesity -- 2.1 Definition of Obesity -- 2.2 Epidemiology -- 2.3 Assessment -- 2.4 Causes, Contributors, and Risk Factors -- 2.5 Genetics -- 2.6 Management -- 2.6.1 Overview of Treatment -- 2.6.2 Comprehensive Models and Behavioral Weight Loss Therapy -- 2.6.3 Dietary Component -- 2.6.4 Physical Activity Component -- 2.6.5 Behavioral Modification Component -- 2.6.6 Pharmacotherapy -- 2.6.7 Dietary Supplements and Procedures to Avoid -- 2.6.8 Bariatric Surgery -- 2.7 Conclusion -- References -- 3: Binge-Related Eating Disorders (Binge Eating Disorder and Bulimia Nervosa) -- 3.1 Epidemiology -- 3.2 Diagnosis and Assessment of BED -- 3.3 Epidemiology of BN -- 3.4 Diagnosis and Assessment of BN -- 3.5 Etiology and Mechanisms of BED and BN -- 3.6 Treatment of BED: General Considerations -- 3.7 Psychotherapies for BED -- 3.8 Pharmacotherapy for BED -- 3.9 Nutritional Recommendations for BED -- 3.10 Best Practices and Guidelines for BED Treatment -- 3.11 Obesity and BED Treatment -- 3.12 Treatment of BN -- 3.13 Treatments for both BED and BN -- 3.14 Conclusion -- References -- Part II: Can the Food Addiction Concept Improve Treatment? -- 4: Problems with Current Approaches to Treating Disorders of Overeating.
4.1 Weight Loss with Available Treatments Is Modest -- 4.2 Maintenance of Weight Loss Is Difficult -- 4.3 The Biology Behind the Difficulty of Weight Loss and Maintenance -- 4.4 Eating Disorder (ED) Treatment Success Rates -- 4.5 ED and Obesity Treatments Give Conflicting Messages -- 4.6 Side Effects of Diets -- 4.7 Limitations and Side Effects of Medications -- 4.8 Side Effects of Bariatric Surgery -- 4.9 Difficulty of Exercising When Obese -- 4.10 Conclusion -- References -- 5: The Food Addiction Concept: History, Controversy, Potential Pitfalls, and Promises -- 5.1 History -- 5.2 Is the FA Concept Valid? -- 5.2.1 Can Obesity Be Explained by FA? -- 5.2.2 Is FA Distinct from BED and Bulimia? -- 5.2.3 Do DSM Criteria for SUD Present in Relation to Food in Humans and Do Symptoms Cluster Together? -- 5.2.4 Is It Valid to Claim Certain Foods Are "Addictive," and Might It Be More Accurate to Consider FA a Behavioral Disorder? -- 5.3 Is the FA Model Useful, and Do Benefits Outweigh Harms? -- 5.3.1 Abstinence-Based Food Plans -- 5.3.2 Self-Efficacy -- 5.3.3 Public Health -- 5.3.4 Stigma -- 5.4 Potential Promises for the Future -- 5.5 Increasing Community Acceptance -- 5.6 Conclusion -- References -- Part III: Clinical Evidence for Food Addiction -- 6: Clinical Evidence for the Validity of Food Addiction -- 6.1 Shared DSM Criteria -- 6.2 Yale Food Addiction Scale Development -- 6.3 SUD and Disordered Eating Co-occur -- 6.4 Sweet Preference, Addiction Transfer, and Cross-Sensitization -- 6.5 Overlapping Neuropsychological, Emotional, and Personality Traits, Psychiatric Diagnoses, and Predisposing Conditions (Trauma and Stress) -- 6.6 Conclusion -- References -- Part IV: Basic Biology of Food Addiction, and Its Overlap with Substance Use Disorders -- 7: Neurobiology and Cognitive Neuroscience of Substance Use Disorders. 7.1 Overview of Substance Use Disorders -- 7.2 Core Brain Regions -- 7.3 Reward -- 7.4 Conditioning: Positive Reinforcement -- 7.5 Motivation: Positive Reinforcement -- 7.6 Tolerance: Downregulation of Dopamine and Opioid System -- 7.7 Withdrawal and Hyperkatifeia -- 7.8 Conditioning and Motivation: Negative Reinforcement -- 7.9 Impulsivity and Executive Function Deficits -- 7.10 Benefits of Understanding the Neurobiology -- 7.11 Conclusion -- References -- 8: Neurobiology and Cognitive Neuroscience of Hedonic Eating -- 8.1 Reward and Hedonic Liking -- 8.2 Conditioning: Positive Reinforcement -- 8.3 Motivation: Positive Reinforcement -- 8.4 Food Reward, Conditioning, and Reward Motivation: Additional Factors -- 8.5 Tolerance and Downregulation of DA and Opioid Systems -- 8.6 Withdrawal -- 8.7 Conditioning and Motivation: Negative Reinforcement -- 8.8 Impulse Control and Executive Function Deficits -- 8.9 Conclusion -- References -- 9: Additional Biological Mechanisms of Hedonic Eating -- 9.1 Interactions Between the Homeostatic System and Hedonic System -- 9.1.1 Anatomy -- 9.1.2 Appetite-Regulating Neuropeptides Modulate Hedonic Eating -- 9.1.3 Appetite-Regulating Neuropeptides Moderate Drug and Alcohol Use -- 9.2 Stress, Hedonic Eating, and the Reward System -- 9.2.1 The Anatomy of the Stress Response -- 9.2.2 Acute and Chronic Stress Promote Hedonic Eating -- 9.3 Genetics -- 9.4 In Utero Exposure -- 9.5 Neuroinflammation -- 9.6 Oxidative Stress -- 9.7 Gut Microbiome and Gut-Brain Axis -- 9.8 Adrenergic System -- 9.9 Sleep and Circadian Rhythm -- 9.10 Serotonin System -- 9.11 Endocannabinoid System -- 9.12 Functional Connectivity -- 9.13 Conclusions -- References -- 10: Treatment-Related Evidence that Food Addiction Is a Valid Construct -- 10.1 Pharmacotherapy-Related Evidence -- 10.1.1 Stimulants. 10.1.2 Opioid Antagonists -- 10.1.3 Topiramate and Zonisamide -- 10.1.4 GLP-1 Agonists -- 10.1.5 Other Medications to Note -- 10.2 Bariatric Surgery -- 10.3 Conclusion -- References -- 11: Highly Palatable Foods Are Addictive -- 11.1 Problematic and "Addictive" Foods -- 11.2 Association Between HP Food Intake and Addiction in Animal Models -- 11.3 Association Between HP Food Intake and Weight Gain/Disordered Eating in Humans -- 11.4 Why Are HP Foods More Associated with Addictive Eating Patterns? -- 11.4.1 Innate Preferences -- 11.4.2 Conditioning from Rapid Post-oral Glucose Rise -- 11.4.3 Stimulation of Reward System by HP Foods -- 11.4.4 Effects on Inflammatory Processes, Oxidative Stress and Gut Microbiome -- 11.4.5 Cessation Leads to Withdrawal -- 11.4.6 Adverse Effects on Mood and Anxiety -- 11.4.7 Reduction in Executive Function -- 11.4.8 Reduction in Satiety Due to Changes in Homeostatic Feeding -- 11.4.9 Individual Variability -- 11.4.10 Feeding Patterns Influence Food Addiction -- 11.5 State Effects of Hunger/Food Restriction on Reward Circuitry and Brain Function -- 11.6 Artificial Sweeteners and Sugar Substitutes -- 11.7 What Should Be Considered Addictive Food? -- 11.8 Conclusion -- References -- Part V: Assessment and Treatment of Food Addiction -- 12: Evaluation of Food Addiction: Importance, Epidemiology, Diagnosis, and Assessment -- 12.1 Importance of Assessing for Food Addiction -- 12.2 Epidemiology of FA -- 12.3 YFAS: Scoring and Interpretation -- 12.4 Other Important Assessment Considerations and Common Comorbidities -- 12.4.1 SUD -- 12.4.2 ED History -- 12.4.3 Obesity History and Related Health Concerns -- 12.4.4 Psychiatric Comorbidity -- 12.5 Conclusion -- References -- 13: How to Treat Food Addiction from a Nutritional Perspective: Consideration of Diet and Abstinence. 13.1 Nutritional Approaches and Consideration of Abstinence -- 13.2 Related Tips -- 13.2.1 Increase Satiety and Brain Health-Promoting Foods -- 13.2.2 Do Not Over-restrict Calorie Intake -- 13.2.3 Realize that Craving Will Diminish with Time in Recovery -- 13.2.4 Abstinence Is Not Absolute: Avoid All-or-Nothing Thinking -- 13.2.5 Is It Better to Start More Extreme or Use a Graded Approach During Initiation? -- 13.2.6 Track Progress -- 13.3 How to Incorporate FA Treatment into ED Treatment Programming -- 13.4 What to Do with "Normal Weight" FA Patients? -- 13.5 Conclusion -- References -- 14: Clinical Applications of the Food Addiction Concept -- 14.1 Treatment Overview -- 14.2 Supplemental Programmatic Elements Which Might Be Useful for Treatment of FA -- 14.2.1 Psychoeducation: FA Is a Brain-Based Disorder -- 14.2.2 Psychosocial Interventions -- 14.2.2.1 CBT -- 14.2.2.2 Behavioral Weight Management -- 14.2.2.3 Motivational Interviewing (MI) -- 14.2.2.4 Psychotherapy to Reduce Negative Affect States, Improve Emotion Regulation, and Address Alexithymia -- 14.2.2.5 Mindfulness-Based (MB) Approaches -- 14.2.2.6 Body Image Work -- 14.2.3 Importance of Sleep -- 14.2.4 Importance of Exercise -- 14.2.5 Importance of Getting Psychiatric and Psychological Care -- 14.2.6 Neuromodulation Techniques -- 14.2.7 12-Step Programs and Other Support -- 14.2.8 Medications -- 14.2.9 Bariatric Surgery -- 14.3 Subtyping and FA Treatment Matching -- 14.3.1 Within-FA Treatment Matching -- 14.3.2 Using FA as a Treatment Matching Variable for Patients with Obesity and BE -- 14.4 Conclusion -- References -- Part VI: Research Possibilities -- 15: Emerging Treatments and Areas for Future Research -- 15.1 Emerging Treatments for Disordered Eating -- 15.1.1 Neurostimulation -- 15.1.2 Real-Time fMRI (Rt-fMRI) Neurofeedback Training. 15.1.3 Cognitive Training. |
| Record Nr. | UNINA-9910502621703321 |
|
Wilcox Claire E.
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Impact of polycystic ovary, metabolic syndrome and obesity on women health . Volume 8 Frontiers in gynecological endocrinology / / Andrea R. Genazzani [and three others], editors
| Impact of polycystic ovary, metabolic syndrome and obesity on women health . Volume 8 Frontiers in gynecological endocrinology / / Andrea R. Genazzani [and three others], editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (227 pages) |
| Disciplina | 618.11 |
| Collana | ISGE Series |
| Soggetto topico |
Polycystic ovary syndrome
Metabolic syndrome Obesity Malalties de l'ovari Quistos Síndrome metabòlica Obesitat Ginecologia endocrina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-63650-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- 1: The Brain Phenotype in Polycystic Ovary Syndrome (PCOS): Androgens, Anovulation, and Gender -- 1.1 Introduction -- 1.2 Anovulation Reflects the PCOS Brain Phenotype -- 1.3 Neuroregulation of GnRH and the Brain Phenotype in PCOS -- 1.4 Gender Identity and Sexual Orientation -- 1.5 Summary -- References -- 2: Adolescence: A High-Risk Period for PCOS Development? -- 2.1 The Role of Peri-Pubertal Obesity -- 2.2 Hyperandrogenism -- 2.3 GnRH Dysregulation -- 2.4 Brain Disorders -- 2.5 Endocrine-Disrupting Chemicals -- 2.6 Gut Microbiota -- 2.7 AMH -- 2.8 Conclusions -- References -- 3: Toward Adolescent Prevention of Adult Anovulation in Polycystic Ovary Syndrome -- 3.1 Definition, Origins, and Diagnosis of Adolescent PCOS -- 3.2 Treatment of Adolescent PCOS: Lifestyle, Estro-Progestagen, SPIOMET -- 3.3 SPIOMET Experience in Adolescent Girls: Limited but Promising -- 3.4 Perspective -- References -- 4: Environmental Factors Responsible for Obesity and Insulin Resistance in Polycystic Ovary Syndrome -- 4.1 Endocrine-Disrupting Chemicals -- 4.1.1 Bisphenol A -- 4.2 Advanced Glycation End Products -- 4.2.1 Vitamin D -- References -- 5: Pathogenesis of PCOS: From Metabolic and Neuroendocrine Implications to the Choice of the Therapeutic Strategy -- 5.1 Introduction -- 5.2 Physiopathology of the PCOS Patients -- 5.2.1 Weight and Metabolism -- 5.2.2 Hyperandrogenism -- 5.2.3 Insulin Resistance -- 5.3 New Perspectives in the Pathogenesis of PCOS -- 5.4 Genetics, Metabolism, and PCOS -- 5.5 The Management of Infertility in PCOS Patients -- 5.5.1 Lifestyle Modification -- 5.5.2 Bariatric Surgery -- 5.5.3 Metformin -- 5.5.4 Clomiphene Citrate -- 5.5.5 Letrozole -- 5.5.6 Ovarian Drilling -- 5.5.7 Gonadotropins and IVF -- 5.5.8 Inositols -- 5.5.9 Alpha-Lipoic Acid -- 5.6 Conclusions.
References -- 6: Polycystic Ovary Syndrome: Considerations About Therapeutic Strategies Choices from Fertile Life to Menopause -- 6.1 Introduction -- 6.2 Endocrine Profile of PCOS -- 6.3 Insulin Resistance (IR) and Compensatory Hyperinsulinism -- 6.4 How to Manage and What to Do in PCOS? -- 6.5 Estrogen-Progestin Preparations and PCOS -- 6.6 No Contraception but Let's Overcome Dysmetabolism! -- 6.7 Long-Term Consideration for PCOS! -- References -- 7: Impact of Polycystic Ovary Syndrome, Metabolic Syndrome, Obesity, and Follicular Growth Arrest in Women Health -- 7.1 Introduction -- 7.2 PCOS and Metabolic Syndrome Linkage -- 7.2.1 Insulin Resistance and Hyperinsulinism in PCOS -- 7.2.2 Role of Adipose Tissue in Insulin Resistance in PCOS -- 7.2.3 Role of Androgen in Insulin Resistance -- 7.3 Metabolic Syndrome, Hyperandrogenism, and Follicular Growth Arrest in PCOS -- 7.4 Intraovarian Mechanism of Follicular Growth Arrest in PCOS -- 7.5 Anti-Müllerian Hormone (AMH) and Follicular Growth Arrest -- 7.6 Dysregulation of Ovarian Angiogenesis and Estrogen Metabolites in the Follicular Growth Arrest -- 7.7 Conclusions -- References -- 8: Quality of Life and Sexual Health -- 8.1 Quality of Life -- 8.1.1 Hirsutism and Acne -- 8.1.2 Body Weight -- 8.1.3 Menstruation -- 8.1.4 Infertility -- 8.1.5 Psychological Distress (Depression and Anxiety) -- 8.2 Sexual Health -- 8.2.1 Impact of PCOS Traits on Sexual Function -- 8.2.2 General Impact of PCOS on Sexual Function -- 8.2.3 Androgens and Sexual Function in PCOS -- 8.3 Conclusions -- References -- 9: Infertility Management in Lean Versus Obese PCOS -- 9.1 Introduction -- 9.2 Pathophysiology of PCOS -- 9.2.1 Insulin Resistance and Hyperandrogenaemia -- 9.2.2 Obesity and Fertility -- 9.2.3 Obesity and Ovulatory Dysfunction -- 9.2.4 Lean Phenotype and Fertility. 9.2.5 Effect on Oocytes and Embryos -- 9.2.6 Effect on Endometrium -- 9.3 Management of Infertility -- 9.3.1 Lifestyle Modification in Obese PCOS -- 9.3.2 Lifestyle Modification in Lean PCOS -- 9.3.3 Bariatric Surgery -- 9.3.4 Anti-Obesity Drugs -- 9.4 Oral Contraceptive Pills (OCP) [31] -- 9.5 Ovulation Induction -- 9.5.1 Oral Ovulation Inducing Agents -- 9.5.2 Gonadotropins -- 9.5.3 GnRH Analogues -- 9.6 Laparoscopic Ovarian Drilling (LOD) -- 9.7 Assisted Reproductive Technologies (ART) -- 9.8 Insulin Sensitizers -- 9.8.1 Metformin -- 9.8.2 Inositols -- 9.8.3 Other Adjuvants -- 9.9 Psychological Intervention -- 9.9.1 Difference in Results between Obese and Lean PCOS -- 9.10 Preventing Complications -- 9.11 Conclusion -- References -- 10: Polycystic Ovary Syndrome: Fertility Treatment Options -- 10.1 Introduction -- 10.2 Fertility Treatment Options -- 10.2.1 Lifestyle Change for Weight Loss -- 10.2.2 Pharmacological and Surgical Ovulation Induction -- 10.2.2.1 Letrozole -- 10.2.2.2 Clomiphene Citrate -- 10.2.2.3 Metformin -- 10.2.2.4 Gonadotropins -- 10.2.2.5 Assisted Reproduction Technology -- 10.2.2.6 Ovarian Drilling -- 10.2.3 Other Treatment Options to Enhance Fertility -- 10.3 Selecting the Optimal Fertility Treatment Option -- 10.4 Conclusions -- References -- 11: Management of PCOS Women Preparing Pregnancy -- 11.1 Introduction -- 11.2 Pathophysiology of PCOS -- 11.3 Long-Term Consequences of PCOS -- 11.4 Treatment Targets -- 11.4.1 Lifestyle -- 11.4.2 Hyperandrogenism -- 11.4.3 Identifying Treatment Priorities in PCOS -- 11.4.4 Obesity -- 11.5 Insulin Resistance and Diabetes Mellitus -- 11.5.1 Decreased Fertility, Adverse Pregnancy Outcomes -- 11.6 Conclusion -- References -- 12: Impact of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Obesity on Women's Health -- 12.1 Introduction. 12.2 Polycystic Ovarian Syndrome (PCOS) and Women's Health -- 12.2.1 PCOS and Fertility -- 12.2.2 PCOS and CVD Risk -- 12.2.3 PCOS and Depression -- 12.2.4 PCOS and Cancer Risk -- 12.3 Metabolic Syndrome (MetS) and Women's Health -- 12.3.1 MetS and Fertility -- 12.3.2 MetS and CVD Risk -- 12.3.3 MetS and Depression -- 12.4 Obesity: The Key Common Denominator in Women's Health -- 12.4.1 Obesity and Fertility -- 12.4.2 Obesity and Pregnancy -- 12.4.3 Obesity and Cancer Risk -- References -- 13: Pregnancy Outcome and Metabolic Syndrome -- 13.1 Introduction -- 13.2 Metabolic Syndrome, Obesity, and Pregnancy Complications -- 13.3 Inflammation, Insulin Resistance, and Oxidative Stress -- 13.4 Prevention of Adverse Obstetric Complications -- References -- 14: The Role of Insulin Resistance in Benign Breast Disease -- 14.1 Principles of Breast Endocrinology -- 14.2 Insulin -- 14.3 Benign Breast Disease -- 14.4 Benign Breast Disease and Breast Carcinoma -- 14.5 Conclusion -- References -- 15: Polycystic Ovary Syndrome and Inflammation -- 15.1 Introduction -- 15.2 Obesity and the PCOS -- 15.3 Inflammation and PCOS -- 15.3.1 Inflammation during Reproductive Life -- 15.3.2 Inflammation in Postmenopausal PCOS Women -- 15.4 Effect of Diet and Exercise on Inflammation -- 15.5 Effect of Probiotic and Synbiotic on Inflammation -- 15.6 Effect of Soy on Inflammation -- 15.7 Vitamin D Supplementation -- 15.8 Effect of Mineral Supplementation on Inflammation -- 15.9 Coenzyme Q10 Supplementation -- 15.10 Final Remarks -- References -- 16: Metabolic Changes at the Menopausal Transition -- 16.1 Introduction -- 16.2 Fat Distribution, Obesity, and Metabolic Syndrome (MS) -- 16.3 Relationship between Obesity, MS, and Menopausal Transition -- 16.3.1 Lipid Metabolism and Menopausal Transition. 16.3.2 The Management of Obesity and MS during Perimenopause -- 16.3.3 How to Prevent Weight Gain -- 16.4 Cardiovascular Disease and Menopause -- 16.5 Conclusions -- References -- 17: Cardiovascular Impact of Metabolic Abnormalities -- 17.1 Introduction -- 17.2 Lipids and Lipoproteins: What Happens in Menopause -- 17.3 Lipids and Lipoproteins: Effect of HRT on Lipids -- 17.4 Glucose: What Happens in Menopause -- 17.5 Glucose: Effect of HRT on Glucose -- 17.5.1 Hypertension: What Happens in Menopause -- 17.5.2 Hypertension: Effect of HRT on Hypertension -- 17.5.3 Obesity: What Happens in Menopause -- 17.5.4 Obesity: Effect on HRT on Weight -- 17.5.5 Inflammatory Markers: What Happens in Menopause -- 17.5.6 Inflammatory Markers: Effect of HRT on Inflammatory Markers -- 17.5.7 Vascular Function/VTE: What Happens in Menopause -- 17.6 Vascular Function/VTE: Effect of HRT on Vascular Function -- 17.7 Conclusion -- References -- 18: How to Prevent, Diagnose, and Treat Gynecological Cancer in PCO Patients? -- 18.1 Introduction -- 18.2 Endometrial Cancer Overview -- 18.3 Etiological and Molecular Mechanisms -- 18.4 Prevention of Endometrial Cancer -- 18.5 Place of Hormonal Prevention -- 18.5.1 Place of Weight Control -- 18.5.2 Place of Metformin -- 18.6 Diagnosis of Endometrial Hyperplasia and Cancer -- 18.7 Risk of Progression of Endometrial Hyperplasia -- 18.8 Treatment of Endometrial Hyperplasia and Cancer -- 18.8.1 Endometrial Hyperplasia -- 18.8.2 Endometrial Cancer -- 18.9 Conclusion -- References. |
| Record Nr. | UNINA-9910506384103321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Obesity and cancer / / Shashank Kumar and Sanjay Gupta (editors)
| Obesity and cancer / / Shashank Kumar and Sanjay Gupta (editors) |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (363 pages) |
| Disciplina | 616.994071 |
| Soggetto topico |
Obesity
Obesity - Complications Obesitat Càncer |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-1846-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495198003321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Obesity and its impact on health / / Methil Kannan Kutty, Asita Elengoe, editors
| Obesity and its impact on health / / Methil Kannan Kutty, Asita Elengoe, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (195 pages) |
| Disciplina | 616.398 |
| Soggetto topico |
Obesity
Obesitat |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-336-408-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910483412703321 |
| Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Obesity science & practice
| Obesity science & practice |
| Pubbl/distr/stampa | [Hoboken, New Jersey] : , : John Wiley & Sons Inc., , [2015]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.398 |
| Soggetto topico |
Obesity
Obesitat Nutrició |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. Revistes electròniques. |
| Soggetto non controllato | Metabolic & Nutritional Diseases |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Obesity science and practice |
| Record Nr. | UNISA-996200355203316 |
| [Hoboken, New Jersey] : , : John Wiley & Sons Inc., , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Obesity science & practice
| Obesity science & practice |
| Pubbl/distr/stampa | [Hoboken, New Jersey] : , : John Wiley & Sons Inc., , [2015]- |
| Descrizione fisica | 1 online resource |
| Disciplina | 616.398 |
| Soggetto topico |
Obesity
Obesitat Nutrició |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. Revistes electròniques. |
| Soggetto non controllato | Metabolic & Nutritional Diseases |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Obesity science and practice |
| Record Nr. | UNINA-9910134946103321 |
| [Hoboken, New Jersey] : , : John Wiley & Sons Inc., , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Obesity, Bariatric and Metabolic Surgery [[electronic resource] ] : A Comprehensive Guide / / edited by Sanjay Agrawal
| Obesity, Bariatric and Metabolic Surgery [[electronic resource] ] : A Comprehensive Guide / / edited by Sanjay Agrawal |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (Approx. 1000 p.) |
| Disciplina | 617 |
| Soggetto topico |
Surgery
Gastroenterology Diseases Obesitat Cirurgia de l'obesitat |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-54064-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Introduction to Obesity -- 2 Etiopathogenesis of Obesity -- 3 Gut-derived Hormones and Energy Homeostasis -- 4 Health Consequences–Obesity Associated Comorbidities -- 5 Medical Management of Obesity -- 6 Historical Perspectives of Bariatric Surgery -- 7 Evidence Base for Bariatric Surgery -- 8 Patient Selection in Bariatric Surgery -- 9 Procedure Selection in Bariatric Surgery -- 10 Preoperative Medical Evaluation of the Bariatric Surgery Patient -- 11 Perioperative Dietary Evaluation of the Bariatric Surgery Patient -- 12 Psychological Assessment of the Bariatric Surgery Patient -- 13 Anaesthesia Considerations in the Obese Patient -- 14 Perioperative Risk Scoring System in Bariatric Surgery -- 15 The Structure and Role of the Multidisciplinary Team in Bariatric Surgery -- 16 Nursing Care of the Bariatric Surgery Patient -- 17 Perioperative Management of the Bariatric Surgery Patient -- 18 Enhanced Recovery after Bariatric Surgery -- 19 Laparoscopic Roux-en-Y Gastric Bypass: The Linear Technique -- 20 Laparoscopic Roux-en-Y Gastric Bypass: The Circular Stapler Technique (Including Transoral as well as Transabdominal Anvil Placement) -- 21 Laparoscopic Roux-en-Y Gastric Bypass: Hand-Sewn Technique -- 22 Laparoscopic Roux-en-Y Gastric Bypass: The Fully Stapled Technique -- 23 Laparoscopic Roux-en-Y Gastric Bypass: Complications- Diagnosis and Management -- 24 Laparoscopic Roux-en-Y Gastric Bypass: Outcomes -- 25 Laparoscopic Roux-en-Y Gastric Bypass: Current Controversies -- 26 Laparoscopic Sleeve Gastrectomy: The Technique -- 27 Laparoscopic Sleeve Gastrectomy: Complications, Diagnosis and Management -- 28 Laparoscopic Sleeve Gastrectomy: Outcomes -- 29 Laparoscopic Sleeve Gastrectomy: Current Controversies -- 30. Laparoscopic Mini-Gastric Bypass Technique -- 31. Laparoscopic Mini-Gastric Bypass Complications -- 32. Laparoscopic Mini-Gastric Bypass Outcome -- 33 Laparoscopic Adjustable Gastric Banding: The Technique -- 34 Laparoscopic Adjustable Gastric Banding: Complications- Diagnosis and Management -- 35 Laparoscopic Adjustable Gastric Banding: Outcomes -- 36 Laparoscopic Adjustable Gastric Banding: Current Controversies -- 37 Reduced Port Laparoscopic Bariatric Surgery -- 38 Single Incision Laparoscopic Roux-en-Y Gastric Bypass -- 39 Single Incision Laparoscopic Sleeve Gastrectomy -- 40 Single Incision Laparoscopic Adjustable Gastric Banding -- 41 Robotic Assisted Bariatric Surgery -- 42 Revisional Surgery after Vertical Banded Gastroplasty -- 43 Revisional Surgery after Laparoscopic Roux-en-Y Gastric Bypass -- 44 Revisional Surgery after Laparoscopic Sleeve Gastrectomy -- 45 Revisional Bariatric Surgery after Laparoscopic Adjustable Gastric Banding -- 46 Laparoscopic Biliopancreatic Diversion with Duodenal Switch (BPD-DS) Surgery -- 47 Laparoscopic Biliopancreatic Diversion (BPD) Surgery -- 48 Laparoscopic Banded Gastric Bypass Surgery -- 49 Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S) Surgery -- 50 Laparoscopic Gastric Plication -- 51 Laparoscopic Gastric Pacing -- 52 Intragastric Balloon Treatment for Obesity -- 53 Endoscopic Duodeno-Jejunal Bypass Sleeve Treatment for Obesity -- 54 Newer Endoluminal Interventions for Obesity -- 55 Endoscopic Treatment of Complications after Bariatric Surgery -- 56 Mechanisms of Action of Bariatric Surgical Procedures -- 57 Glycemic Control and Reduction of Cardiovascular Risk following Bariatric Surgery -- 58 Resolution of Obesity Associated Comorbidities (Diabetes, Hypertension, Sleep Apnea and Metabolic Syndrome) following Bariatric Surgery -- 59 Metabolic Surgery for Type 2 Diabetes Mellitus in Patients with Body Mass Index less than 35 kg/m2 -- 60 Ileal Interposition with Sleeve Gastrectomy for Type 2 Diabetes Mellitus and Metabolic Syndrome -- 61 Training in Bariatric Surgery -- 62 Bariatric Surgery Data Management and Reporting Worldwide -- 63 Surgical Review Corporation (SRC) Center of Excellence Programs for Bariatric Surgery -- 64 International Federation for Surgical Obesity (IFSO) Center of Excellence Program for Bariatric Surgery -- 65 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) by American Society for Metabolic and Bariatric Surgery (ASMBS) for Bariatric Surgery -- 66 Medicolegal Issues in Bariatric Surgery -- 67 Nutritional Management of the Bariatric Surgery Patient -- 68 Management of Extreme Obesity (Body Mass Index greater than 60 Kgm2) -- 69 Respiratory Considerations and Effect of Bariatric Surgery in the Obese Patient -- 70 Infertility, Pregnancy and Bariatric Surgery -- 71 Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric Surgery -- 72 Cancer, Obesity and Bariatric Surgery -- 73 Psychological Issues Before and After Bariatric Surgery -- 74 Health-Related Quality of Life Before and After Bariatric Surgery -- 75 Management of Bariatric Emergencies by the General Surgeon -- 76 The Role of Primary Care in Bariatric Surgery -- 77 Intensive Care and Obesity -- 78 Radiological Imaging in Bariatric Surgery -- 79 Adolescent Bariatric Surgery -- 80 Body Contouring after Bariatric Surgery. |
| Record Nr. | UNINA-9910495348903321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Obesitat
(12)
- Obesity (5)
- Nutrició (3)
- Càncer (2)
- Trastorns del metabolisme (2)